Luigi Grazioli1, Riccardo Faletti2, Barbara Frittoli1, Giacomo Battisti3, Roberta Ambrosini1, Laura Romanini1, Marco Gatti3, Paolo Fonio3. 1. Department of Radiology, Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123, Brescia, Italy. 2. Department of Surgical Sciences, Radiology Institute, University of Turin, Via Genova 3, 10126, Turin, Italy. riccardo.faletti@unito.it. 3. Department of Surgical Sciences, Radiology Institute, University of Turin, Via Genova 3, 10126, Turin, Italy.
Abstract
AIMS: To evaluate motion artifacts, breath-hold failure, acute transient dyspnea, and clinical parameters during hepatic arterial phase of gadoxetate disodium-enhanced magnetic resonance (MR) imaging. METHODS: This was an institutional review board-approved observational prospective study (written informed consent acquired) performed in 250 consecutive patients, who underwent liver MR with a multiarterial phase technique. Oxygen saturation (SatO2) and heart rate (HR) were monitored, while patients reported subjective symptoms. Breath-holds were assessed using prospective acquisition correction technique (PACE) monitors. Three readers independently analyzed all images to establish the presence of motion artifacts. Nonparametric statistical testing and Fleiss' kappa were used. RESULTS: No statistical differences in SatO2 and HR values were observed during the entire length of MR examination. The PACE graphs showed an altered breath-hold in 16/250 patients (6.4%), however only 6 patients self-reported symptoms during the procedure, and among these 6 subjects, only 2 suffered from acute transient dyspnea (0.8%). Motion-related artifacts increased mostly in the third arterial phase of gadoxetate disodium acquisition (p < 0.0001): The artifacts incidence was 2.9% in the first phase; 4.0% in the second; and 19.5% in the third. This increase was mainly due to patients' inability to hold their breath for the entire duration of the examination. However, at least one gadoxetate disodium arterial phase without motion artifacts and adequate for acquisition timing, was acquired in all MR examinations. CONCLUSION: The incidence of breath-hold failure and acute transient dyspnea after gadoxetate disodium administration increased during the third arterial phase only. Our protocol allowed the acquisition of at least one arterial phase not compromised by motion artifacts and adequate for acquisition timing, in all patients.
AIMS: To evaluate motion artifacts, breath-hold failure, acute transient dyspnea, and clinical parameters during hepatic arterial phase of gadoxetate disodium-enhanced magnetic resonance (MR) imaging. METHODS: This was an institutional review board-approved observational prospective study (written informed consent acquired) performed in 250 consecutive patients, who underwent liver MR with a multiarterial phase technique. Oxygen saturation (SatO2) and heart rate (HR) were monitored, while patients reported subjective symptoms. Breath-holds were assessed using prospective acquisition correction technique (PACE) monitors. Three readers independently analyzed all images to establish the presence of motion artifacts. Nonparametric statistical testing and Fleiss' kappa were used. RESULTS: No statistical differences in SatO2 and HR values were observed during the entire length of MR examination. The PACE graphs showed an altered breath-hold in 16/250 patients (6.4%), however only 6 patients self-reported symptoms during the procedure, and among these 6 subjects, only 2 suffered from acute transient dyspnea (0.8%). Motion-related artifacts increased mostly in the third arterial phase of gadoxetate disodium acquisition (p < 0.0001): The artifacts incidence was 2.9% in the first phase; 4.0% in the second; and 19.5% in the third. This increase was mainly due to patients' inability to hold their breath for the entire duration of the examination. However, at least one gadoxetate disodium arterial phase without motion artifacts and adequate for acquisition timing, was acquired in all MR examinations. CONCLUSION: The incidence of breath-hold failure and acute transient dyspnea after gadoxetate disodium administration increased during the third arterial phase only. Our protocol allowed the acquisition of at least one arterial phase not compromised by motion artifacts and adequate for acquisition timing, in all patients.
Authors: Philipp M Kazmierczak; Daniel Theisen; Kolja M Thierfelder; Wieland H Sommer; Maximilian F Reiser; Mike Notohamiprodjo; Konstantin Nikolaou Journal: Invest Radiol Date: 2015-03 Impact factor: 6.016
Authors: Matthew S Davenport; Mustafa R Bashir; Jason A Pietryga; Joseph T Weber; Shokoufeh Khalatbari; Hero K Hussain Journal: AJR Am J Roentgenol Date: 2014-07-23 Impact factor: 3.959
Authors: E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi Journal: Eur Radiol Date: 2015-07-21 Impact factor: 5.315
Authors: Marco Gatti; Marco Calandri; Laura Bergamasco; Fatemeh Darvizeh; Luigi Grazioli; Riccardo Inchingolo; Davide Ippolito; Stefano Rousset; Andrea Veltri; Paolo Fonio; Riccardo Faletti Journal: Radiol Med Date: 2020-01-08 Impact factor: 3.469
Authors: M-L Kromrey; D Tamada; H Johno; S Funayama; N Nagata; S Ichikawa; J-P Kühn; H Onishi; U Motosugi Journal: Eur Radiol Date: 2020-06-17 Impact factor: 5.315
Authors: Christoph J Zech; Ahmed Ba-Ssalamah; Thomas Berg; Hersh Chandarana; Gar-Yang Chau; Luigi Grazioli; Myeong-Jin Kim; Jeong Min Lee; Elmar M Merkle; Takamichi Murakami; Jens Ricke; Claude B Sirlin; Bin Song; Bachir Taouli; Kengo Yoshimitsu; Dow-Mu Koh Journal: Eur Radiol Date: 2019-08-05 Impact factor: 5.315
Authors: Carl Guillaume Glessgen; Hanns-Christian Breit; Tobias Kai Block; Elmar Max Merkle; Tobias Heye; Daniel Tobias Boll Journal: Eur Radiol Date: 2021-07-29 Impact factor: 5.315